



sanofi aventis



Bristol-Myers Squibb

November 3, 2011

Dear Health Care Professional:

**Subject: Risk of potential patient harm associated with brand name confusion involving Pradox<sup>®</sup> (dabigatran etexilate) and Plavix<sup>®</sup> (clopidogrel bisulfate).**

Boehringer Ingelheim (Canada) Ltd., and sanofi-aventis Canada Inc. (on behalf of Bristol-Myers Squibb Sanofi Canada partnership) in consultation with Health Canada, would like to alert you to the risk of medication errors associated with name confusion between the anticoagulant Pradox<sup>®</sup> (dabigatran etexilate) from Boehringer Ingelheim (Canada) Ltd. and the antiplatelet drug Plavix<sup>®</sup> (clopidogrel bisulfate) from sanofi-aventis Canada Inc.

Since January 2011, a total of 5 Canadian cases, associated with drug name confusion between Pradox<sup>®</sup> and Plavix<sup>®</sup>, have been received by Boehringer Ingelheim (Canada) Ltd. and Health Canada, including 1 case resulting in patient harm (non-serious bleeding after a medical procedure). An additional 2 reports of concern were received from health care professionals about the potential for confusion between the names of these two drugs.

- The Pradox<sup>®</sup> and Plavix<sup>®</sup> names, verbally and by script have been mistaken for one another. These mix-ups have been associated with similarities in orthographics, phonetics, strength, and use in patients with cardiovascular disorders.
- Receiving Pradox<sup>®</sup> instead of Plavix<sup>®</sup> or vice versa, may result in patient harm, including increased risk of bleeding, stroke, systemic embolism, venous thromboembolic events (VTE), atherothrombotic events or other unknown medical outcomes.
- The patient is also at risk of receiving incorrect concomitant medications or medical procedures when Pradox<sup>®</sup> or Plavix<sup>®</sup> is noted in patient history in error as a result of name confusion.
- To reduce the potential for name confusion errors, healthcare professionals are encouraged to include the generic name dabigatran when referring to Pradox<sup>®</sup>, or the name clopidogrel when referring to Plavix<sup>®</sup>. Spelling the name of the medication for verbal prescriptions or medication reconciliation (e.g. emergency room triage), is also suggested.

Pradox<sup>®</sup> (dabigatran), an oral anticoagulant (direct thrombin inhibitor), was first marketed in Canada in 2008, for the prevention of VTE in patients following hip or knee replacement surgery. In October 2010, Pradox<sup>®</sup> received a new indication for prevention of stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation is appropriate. Pradox<sup>®</sup> is available in 75mg, 110mg and 150mg capsules.<sup>1</sup>

Plavix<sup>®</sup> (clopidogrel), an oral platelet aggregation inhibitor, was first marketed in Canada in 1998, for use as secondary prevention of atherothrombotic events (myocardial infarction or stroke) in patients with atherosclerosis. Plavix<sup>®</sup> is also indicated in combination with ASA for the prevention of atherothrombotic events in patients with acute coronary syndromes. In February 2011, Plavix<sup>®</sup> received a new indication, in combination with low-dose ASA, for the prevention of stroke in patients with atrial fibrillation, who are not suitable for treatment with an anticoagulant. Plavix<sup>®</sup> is available in 75mg and 300mg tablets.<sup>2</sup>

Boehringer Ingelheim Canada Ltd., and sanofi-aventis Canada Inc. (on behalf of Bristol-Myers Squibb Sanofi Canada partnership), in consultation with Health Canada, are working on measures to reduce the risk associated with medication errors related to name confusion issues between Pradox<sup>®</sup> and Plavix<sup>®</sup>.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of medication errors relating to name confusion between Pradox<sup>®</sup> and Plavix<sup>®</sup> should be reported to Boehringer Ingelheim (Canada) Ltd.,

sanofi-aventis Canada Inc. or Health Canada. Serious or unexpected adverse reactions in patients receiving Pradox<sup>®</sup> should be reported to Boehringer Ingelheim (Canada) Ltd. or Health Canada. Any case of serious or unexpected adverse reactions in patients receiving Plavix<sup>®</sup> should be reported to sanofi-aventis Canada Inc. or to Health Canada. Medication incidents/errors can also be reported to the Institute for Safe Medication Practices (ISMP) Canada through the Canadian Medication Incident Reporting and Prevention System (<http://www.ismp-canada.org/cmiprs.htm>).

Boehringer Ingelheim (Canada) Ltd.,  
5180 South Service Rd.  
Burlington, ON, L7L 5H4  
Tel: 1 (800) 263-5103 Ext. 84603.

<http://www.boehringer-ingelheim.ca/en/contact.html>

sanofi-aventis Canada Inc.  
2150 St-Elzear Blvd. West  
Laval, Quebec  
H7L 4A8  
Phone: 1-800-265-7927

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)
- Call toll-free at 1-866-234-2345
- Complete a Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program  
Health Canada  
Postal Locator 0701E  
Ottawa, Ontario K1A 0K9

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect<sup>™</sup> Canada Web site in the [Adverse Reaction Reporting](http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php) section (<http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php>). The Reporting Form is also in the *Canadian Compendium of Pharmaceuticals and Specialties*.

**For other health product inquiries related to this communication, please contact Health Canada at:**

Marketed Health Products Directorate

E-mail: [mhpd\\_dpssc@hc-sc.gc.ca](mailto:mhpd_dpssc@hc-sc.gc.ca)

Telephone: 613-954-6522 Fax: 613-952-7738

For full prescribing and dosing information for Pradox<sup>®</sup> see Product Monograph.<sup>1</sup> For full prescribing and dosing information for Plavix<sup>®</sup> see Product Monograph.<sup>2</sup>

A copy of this letter can be found on the Boehringer Ingelheim (Canada) Ltd., website at: [http://www.boehringer-ingelheim.ca/en/human\\_health/our\\_products.html](http://www.boehringer-ingelheim.ca/en/human_health/our_products.html) and also at the sanofi-aventis Canada Inc. site: [www.sanofi-aventis.ca](http://www.sanofi-aventis.ca)

Sincerely,

*original signed by*



Mathias Knecht, M.D.  
Vice President, Medical and Regulatory Affairs  
Boehringer Ingelheim (Canada) Ltd.



Franca Mancino, M.Sc.  
Senior Director, Regulatory Affairs, Pharmacovigilance  
& Medical Quality and Compliance  
sanofi-aventis Canada Inc.

#### References:

1. Pradox<sup>®</sup> Product Monograph, dated June 13, 2011  
<http://webprod3.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp>
2. Plavix<sup>®</sup> Product Monograph, dated May 9, 2011  
<http://webprod3.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp>